Document:

Exhibit 10.28

 

February 13, 2004

 

Steven A. Bourne, CPA

 

RE: Employment Offer

 

Dear Steve:

 

I am pleased to offer you the opportunity to join
Clarus Therapeutics, Inc. as Vice President of Finance and Administration beginning on Monday, February 16, 2004. The specific terms of
this employment offer are outlined below. You will report directly to me in this vital position and will be responsible for directing
the overall financial plans and accounting practices of Clarus. In addition, you will oversee the treasury, accounting, budget, tax and
audit activities of the organization. You will also be responsible for ensuring that Clarus has appropriate financial and accounting system
controls and standards in place. I will also look to you to prepare timely financial and statistical reports for management and/or Board
use. Further, you will additionally serve as Clarus’ Treasurer and Secretary.

 

Your starting salary will $130,000 per year paid
in semi-monthly installments. Future salary increases will be at the discretion of Clarus’ Board of Directors and will be based,
in large part, on an annual performance review and the financial status of the company. In further consideration of your position in the
company, Clarus will grant you, 225,000 shares of stock split between restricted stock (166,667 shares valued at $0.01 per share) and
an option to purchase 58,333 shares of common stock at its fair market value on your first day of employment, namely, $0.10 per share.
Of the initial number of restricted shares, 112,500 will vest immediately as of February 16, 2004. The remaining restricted shares (54,167),
which are subject to repurchase in accordance with your Stock Restriction Agreement), and the option shares (58,333) will vest in equal
monthly installments over a 4-year period with a one-year cliff vesting provision. This means that none of these shares vest during the
first 12 months of your employment whereupon 25% of each stock type will immediately vest on February 16, 2005 so long as you are still
employed by Clarus. After this date, the remaining shares will vest monthly over 36 months. This grant must be ratified by the board of
directors and is subject only to the terms and conditions of Clarus’ stock option plan. Future grant awards will be made based on
company and individual employee performance. Clarus intends to use option grants as a strong performance incentive.

 

In recognition of your role at Clarus, you will
be given certain benefits should your employment be terminated “without cause” (except during the period from February 16,
2005 to January 1, 2005) or if there is a change in control as defined in Appendix A. Specifically, you will receive continuation of salary
and health insurance benefits for up to six (6) months after termination - dependent upon when you obtain other comparable employment.
Furthermore, if a change of control occurs (whether or not your employment is terminated), then all of your then unvested shares of restricted
stock and options will immediately vest. As a condition of any severance package, you will be required to sign a general release of claims
in favor of the Company.

 

     

     

    

 

Clarus will also provide benefits, as outlined
in the enclosed summary. In addition to company holidays, as noted in the attachment hereto, you will also receive three weeks of paid
vacation per calendar year. If you are unable to use all of your vacation in any one year because the workload at Clarus is such that
it is not possible for you to do so, you may rollover up to one week to the next year but may not have a cumulative total of vacation
in excess of four (4) weeks. For 2004, vacation days will be pro-rated based on your starting date.

 

Steve, I believe that you will make a substantial
contribution to Clarus. In doing so, you will be joining a team that is committed to making Clarus a recognized leader in the development
and marketing of androgen-based prescription products, worldwide. Of greater importance from my perspective is the opportunity we will
have to positively impact the health of individuals who use our products.

 

Finally, as a condition of your employment, you
must sign the attached “Inventions, Confidentiality and Noncompetition Agreement.”

 

Please indicate your acceptance of this offer
by signing below and returning a copy of this letter to me by mail or by facsimile. Thank you.

 

Kind Regards,

 

	/s/ Robert E. Dudley, PhD	 
	Robert E. Dudley, PhD	 
	President & CEO	 

 

ACCEPTANCE:

 

	/s/ Steven Bourne	2/13/04	 
	Steven Bourne	Date	 

 

    -2-

     

    

 

Appendix A

 

Definition of Change of Control

 

“Change in Control” shall be deemed
to have occurred if:

 

		(A)	A third person other than Shareholders on the date hereof or their Affiliates, including a “group”
as such term is defined in Section 13(d)(3) of the Securities Exchange Act of 1934, becomes the direct or indirect beneficial owner of
shares of the Company having more than fifty percent (50%) of the total number of votes that may be cast for the election of directors
of the Company;

 

		(B)	The Company sells all or substantially all of its assets;

 

		(C)	The Company enters into any transaction in which more than fifty percent (50%) of the Company’s
voting power is transferred to Persons other than the Shareholders on such date or their Affiliates; or

 

		(D)	The Shareholders of the Company approve dissolution or complete liquidation of the Company.

 

Shareholders means the Shareholders of the Company
on the date hereof and Affiliates means any Persons controlled by, controlling or under common control with any Shareholder. Person means
any person or entity.

 

If the Company accepts an investment for the purpose
of raising cash to fund operations and/or to make an acquisition and such a transaction results in a change in ownership of 50%, then
this shall not be deemed a Change in Control provided that the make up of the Company’s Board of Directors is not changed except
by the sole addition of no more than two (2) new board members to represent the interests of the party(ies) investing in the Company.

 

    -3-

     

    

 

July 12, 2005

 

Clarus Therapeutics, Inc.

500 Skokie Boulevard

Suite 250

Northbrook, Illinois 60062

 

Re: Employment Letter dated
as of February 13, 2004, between Clarus Therapeutics. Inc. (“Clarus”) and Steven A. Bourne (the “Employment Letter”)

 

Gentlemen:

 

The above referenced Employment
Letter provides that I will receive a base salary of $10,833.34 per month, payable semi-monthly. This letter agreement hereby amends such
provision to reflect our mutual agreement to defer an aggregate amount of $5,416.70 of such base salary for the period from July 1, 2005,
through and until November 30, 2005 as follows. Each month during such period, $1,083.34 of such base salary will be deferred.

 

On November 30, 2005, you
and I agree that I will receive from Clarus, if I so elect and at my sole discretion, in full and complete satisfaction of, and as consideration
for, such salary deferral, an unsecured convertible promissory note in the principal amount of $5,416.70, some or all of which, along
with accrued and unpaid interest may be converted into shares of Clarus’ Series A Convertible Preferred Stock (the “Preferred
Shares”) in accordance with all of the terms and conditions set forth in the note in the form of Exhibit A which is attached hereto.

 

In the event that I elect
not to receive the aforesaid unsecured convertible promissory note in the principal amount of $5,416.70, we agree that no further consideration
is due from Clarus to me as deferred compensation referenced herein.

 

	 	By: 	/s/ Steven A. Bourne
	 	 	Name: 	Steven A. Bourne

 

    -4-

     

    

 

January 25, 2006

 

Clarus Therapeutics, Inc.

500 Skokie Boulevard

Suite 250

Northbrook, Illinois 60062

 

Re: Employment Letter dated
as of February 13, 2004, between Clarus Therapeutics, Inc. (“Clarus”) and Steven A. Bourne (the “Employment Letter”)

 

Gentlemen:

 

The above referenced Employment
Letter provides that I will receive a base salary of $10,833.34 per month. payable semi-monthly. By letter agreement dated as of July
12, 2005, you and I agreed to amend such provision to reflect our mutual agreement to defer an aggregate amount of $5,416.70 of such base
salary for the period from July 1, 2005, through and until November 30, 2005, all as set forth in that certain letter agreement (the “Amendment
to Employment Letter” or the “Amendment”). This letter agreement hereby further amends such provision to reflect our
mutual agreement to defer an additional aggregate amount of $1,083.34 of such base salary for the period from December 1, 2005, through
and until December 31, 2005.

 

Said Amendment to Employment
letter also provided that on November 30, 2005, I would receive from Clarus, in full and complete satisfaction of, and as consideration
for, such salary deferral, an unsecured convertible promissory note in the principal amount of $5,416.70 (the “Note”), some
or all of which, along with accrued and unpaid interest could be converted into shares of Clarus’ Series A Convertible Preferred
Stock (the “Preferred Shares”) in accordance with the all of the terms and conditions set forth in the Note in the form of
Exhibit A attached to the Amendment to Employment Letter. Notwithstanding the terms of the Amendment, however, I elected not to receive
the Note on November 30, 2005.

 

On February 28, 2006, you
and I agree that I will receive from Clarus, if I so elect and at my sole discretion, in full and complete satisfaction of, and as consideration
for, the aggregate salary deferral referenced in this letter agreement and the salary deferral referenced in the previous Amendment, an
unsecured convertible promissory note in the principal amount of $6,500.04, some or all of which, along with accrued and unpaid interest
may be converted into the Preferred Shares in accordance with all of the terms and conditions set forth in the Note in the Form of Exhibit
A which is attached hereto.

 

In the event that I elect
not to receive the aforesaid unsecured convertible promissory note in the principal consideration in the principal amount of $6,500.04,
we agree that no further consideration is due from Clarus to me as deferred compensation referenced herein or in the previous Amendment.

 

	 	By: 	/s/ Steven A. Bourne
	 	 	Name: 	Steven A. Bourne

 

    -5-

     

    

 

March 3, 2006

 

Clarus Therapeutics, Inc.

500 Skokie Boulevard

Suite 250

Northbrook, Illinois 60062

 

Re: Extension of Maturity
Date of Amendments to Employment Letter

 

Gentlemen:

 

On January 25, 2006, I entered
into that certain letter agreement attached hereto as Exhibit A (the “January 2006 Letter Agreement”), which references an
amendment to that certain Employment Letter dated as of February 13, 2004, between Clarus Therapeutics. Inc. (“Clarus”) and
Steven A. Bourne (the “Employment Letter”) and further amends said Employment Letter.

 

The January 2006 Letter Agreement
provides that I will receive from Clarus, if I so elect and at my sole discretion, on February 28, 2006, in full and complete satisfaction
of, and as consideration for the aggregate salary deferral referenced therein and in the previous amendment to the Employment Letter,
an unsecured convertible promissory note in the principal amount of $6,500.04, some or all of which, along with accrued and unpaid interest
may be converted into shares of Clarus’ Series A Convertible Preferred Stock (the “Preferred Shares”) in accordance
with all of the terms and conditions set forth in the note in the form of Exhibit B which is attached hereto (the “Note”).
However, this letter agreement will further amend the January 2006 Letter Agreement to extend the maturity date of February 28, 2006 stated
therein until June 30, 2007. Accordingly, at my sole option, I may elect to receive one or more Notes in the aggregate amount of $6,500.04
on or before June 30, 2007.

 

In the event that I elect
not to receive the aforesaid Note(s) in the aggregate principal amount of $6,500.04, we agree that no further consideration is due from
Clarus to me as deferred compensation referenced in either of the two amendments to the Employment Letter.

 

	 	By: 	/s/ Steven A. Bourne
	 	 	Name: 	Steven A. Bourne

 

    -6-

     

    

 

February 6, 2007

 

Clarus Therapeutics, Inc.

500 Skokie Boulevard

Suite 250

Northbrook, Illinois 60062

 

Re: Letter Agreement re: Amendments to Employment
Letter and Conversion of Notes

 

Gentlemen:

 

Background

 

On January 25, 2006, I entered
into that certain letter agreement (the “January 2006 Letter Agreement”), which references a previous amendment to that certain
Employment Letter dated as of February 13, 2004, between Clarus Therapeutics, Inc. (“Clarus”) and Steven A. Bourne (the “Employment
Letter”) (the first letter agreement amendment dated July 12, 2005, hereinafter, the “Amendment to Employment Letter”)
and further amends said Employment Letter.

 

The January 2006 Letter Agreement
provides that I will receive from Clarus, if I so elect and at my sole discretion, on February 28, 2006, in full and complete satisfaction
of, and as consideration for the aggregate salary deferral referenced therein and in the previous amendment to the Employment Letter,
an unsecured convertible promissory note in the principal amount of $6,500.04, some or all of which, along with accrued and unpaid interest
may be converted into shares of Clarus’ Series A Convertible Preferred Stock (the “Series A Shares”) in accordance with
all of the terms and conditions set forth in the note in the form of Exhibit A attached to the Amendment to Employment Letter (the “Note”).
On March 3, 2006, I entered into another letter agreement with you which further amended the January 2006 Letter Agreement to extend the
maturity date of February 28, 2006 stated therein until June 30, 2007. Accordingly, at my sole option, I may elect to receive one or more
Notes in the aggregate amount of $6,500.04 on or before June 30, 2007.

 

In another letter agreement
dated August 2, 2006, (the “Side Letter Agreement”) we agreed, among other things, that if, I elect to receive one or more
Notes up to an aggregate amount of $6,500.04, I will immediately provide written notice to Clarus under, and in accordance with, the terms
of the Note to convert all of the principal amount and then accrued and unpaid interest under the Note into Series A Shares in accordance
with all of the terms of the Note.

 

Agreement

 

The purpose of this Agreement
is to replace the form of the Note previously agreed to and which was attached to the January 2006 Letter Agreement as Exhibit A thereto
with the revised form of Unsecured Convertible Promissory Note in the form of Appendix A which is attached hereto (the “Revised
Note”), which provides for the conversion of all principal and accrued and unpaid interest into shares of Clarus’ Series B
Convertible Preferred Stock (in lieu of the Series A Shares which were contemplated by the January 2006 Letter Agreement). Accordingly,
the Side Letter Agreement is amended as well such that all references therein to Note(s) therein shall be deemed to refer to the Revised
Note(s) and all references to Series A Convertible Preferred Stock shall be deemed to refer to Series B Convertible Preferred Stock.

 

	 	By: 	/s/ Steven A. Bourne
	 	 	Name: 	Steven A. Bourne

 

	Accepted and Agreed	 
	As of the date written above.	 
	 	 
	CLARUS THERAPEUTICS, INC.	 
	 	 	 
	By:	/s/ Robert E. Dudley	 
	 	 	 
	Its:	CEO	 

 

    -7-

     

    

 

June 28, 2007

 

Clarus Therapeutics, Inc.

500 Skokie Boulevard

Suite 250

Northbrook, Illinois 60062

 

Re: Letter Agreement re: Amendments to Employment
Letter and Conversion of Notes

 

Gentlemen:

 

Background

 

On January 25, 2006, I entered
into that certain letter agreement (the “January 2006 Letter Agreement”), which references a previous amendment to that certain
Employment Letter dated as of February 13, 2004, between Clarus Therapeutics, Inc. (“Clarus”) and Steven A. Bourne (the “Employment
Letter”) (the first letter agreement amendment dated July 12, 2005, hereinafter, the “Amendment to Employment Letter”)
and further amends said Employment Letter.

 

The January 2006 Letter Agreement
provides that I will receive from Clarus, if I so elect and at my sole discretion, on February 28, 2006, in full and complete satisfaction
of, and as consideration for the aggregate salary deferral referenced therein and in the previous amendment to the Employment Letter,
an unsecured convertible promissory note in the principal amount of $6,500.04, some or all of which, along with accrued and unpaid interest
may be converted into shares of Clarus’ Series A Convertible Preferred Stock (the “Series A Shares”) in accordance with
all of the terms and conditions set forth in the note in the form of Exhibit A attached to the Amendment to Employment Letter (the “Note”).
On March 3, 2006, I entered into another letter agreement with you which further amended the January 2006 Letter Agreement to extend the
maturity date of February 28, 2006 stated therein until June 30, 2007. Accordingly, at my sole option, I may elect to receive one or more
Notes in the aggregate amount of $6,500.04 on or before June 30, 2007 (the “Payment Date”).

 

In another letter agreement
dated August 2, 2006, (the “Side Letter Agreement”) we agreed, among other things, that if, I elect to receive one or more
Notes up to an aggregate amount of $6,500.04, I will immediately provide written notice to Clarus under, and in accordance with, the terms
of the Note to convert all of the principal amount and then accrued and unpaid interest under the Note into Series A Shares in accordance
with all of the terms of the Note.

 

In another letter agreement
dated February 6, 2007 (the “February 2007 Side Letter Agreement”), we agreed to replace the form of the Note with a revised
form of the Note providing for the conversion of the Note into Series B Convertible Preferred Stock (the “Series B Shares”)
instead of the Series A Shares.

 

Agreement

 

The purpose of this Agreement
is to extend the Payment Date from June 30, 2007 to December 31, 2007 and to replace the form of the Note previously agreed to and which
was attached to the February 2007 Side Letter Agreement as Exhibit A thereto with the revised form of Unsecured Convertible Promissory
Note in the form of Appendix A which is attached hereto (the “Revised Note”), which provides for the conversion of all principal
and accrued and unpaid interest into shares of Clarus’ Series B Convertible Preferred Stock on December 31, 2007 (instead of June
30, 2007). Accordingly, each of the Side Letter Agreement and the February 2007 Side Letter Agreement is amended as well such that all
references therein to Note(s) therein shall be deemed to refer to the Revised Note(s).

 

	 	By: 	/s/ Steven A. Bourne
	 	 	Name: 	Steven A. Bourne

 

	Accepted and Agreed	 
	As of the date written above.	 
	 	 
	CLARUS THERAPEUTICS, INC.	 
	 	 	 
	By:	/s/ Robert E. Dudley	 
	 	 	 
	Its:	CEO	 

 

 

    -8-

     

    

 

AMENDMENT TO

EMPLOYMENT OFFER LETTER

 

This AMENDMENT TO THE EMPLOYMENT
OFFER LETTER, dated December 30, 2008, is by and between CLARUS THERAPEUTICS, INC., a Delaware corporation (the “Company”),
and Steven A. Bourne, CPA (the “Executive”).

 

WHEREAS, the Company and the
Executive entered into an employment offer letter dated February 13, 2004 (the “Agreement”); and

 

WHEREAS, the parties desire
to amend the Agreement to comply with and meet the requirements of the provisions of Section 409A of the Internal Revenue Code of 1986,
as amended (the “Code”).

 

NOW, THEREFORE, the Company
and the Executive, each intending to be legally bound hereby, do mutually covenant and agree as follows:

 

1. Paragraph
3 of the Agreement is amended by deleting the paragraph and replacing it with the following:

 

“In recognition of your role at
Clarus, you will be given certain benefits should your employment be terminated by Clarus “without cause” (except during the
period from February 16, 2005 to January 1, 2006) or if there is a change in control as defined in Appendix A. Specifically if your employment
is terminated without cause by Clarus, you will receive continuation of salary (at the rate then in effect) and health insurance benefits
for up to six (6) months after termination or until you obtain other comparable employment (if earlier). Your salary and benefit continuation
shall commence immediately upon your termination of employment by Clarus without cause. Furthermore, if a change of control occurs (whether
or not your employment is terminated), then all of your then unvested shares of restricted stock and options will immediately vest. Notwithstanding
the foregoing, as a condition of any severance package (e.g., salary and benefit continuation), you will be required to sign a general
release of claims in favor of the Company within the 30 day period following your termination of employment. If you fail to sign such
release in that 30 day period or otherwise revoke that release, your salary and benefit continuation shall immediately cease and any amounts
already paid to you will be subject to collection by Clarus.

 

2. The
Agreement is hereby further amended by adding a new paragraph immediately after paragraph 6 of the Agreement:

 

“The parties intend that this
Agreement will be administered in accordance with Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”).
To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall
be read in such a manner so that all payments hereunder comply with Section 409A of the Code. The parties agree that this Agreement may
be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related
rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. The Company
makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined
to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such
Section.”

 

3. The
Agreement otherwise remains in full force and effect as to all other provisions under said Agreement.

 

    -9-

     

    

 

IN WITNESS WHEREOF, the parties
hereto have executed this Amendment as of the date first above written.

 

	 	CLARUS THERAPEUTICS, INC.
	 	 	 	 
	 	By: 	/s/ Alex Zisson
	 	 	Name: 	Alex Zisson
	 	 	Title:	Board Member, Compensation Committee
	 	 	 	 
	 	By:	/s/ Michael Wasserman
	 	 	Name:	Michael Wasserman
	 	 	Title:	Board Member, Compensation Committee

 

	 	/s/ Robert E. Dudley
	 	Robert E. Dudley, Ph. D
	 	 
	 	/s/ Steven A. Bourne
	 	Steven A. Bourne, CPA

 

[Signature Page to Executive Employment Agreement
Amendment]

 

 

 

-10-Exhibit
10.29

 

September
5, 2019

 

Frank A.
Jaeger

 

RE: Employment
Offer: Chief Commercial Officer

 

Dear Frank:

 

I
am pleased to offer you the opportunity to join Clarus Therapeutics, Inc. as Chief Commercial Officer beginning on a mutually acceptable
day this month but not later than September 30, 2019. The actual first day of your employment shall be referred to in this letter agreement
as the “Start Date”. The specific terms of your employment are outlined below.

 

You
will report to me and it is expected that you will be a very important member of Clarus’s executive team. Your office will be located
at Clarus’s offices, presently located in Northbrook, IL. As part of your employment, you will be expected to travel as necessary
to achieve Clarus’s objectives - particularly those related to the commercialization of JATENZO. Overall, your principal duties
are expected to include:

 

		●	Provide
                                            strategic and organizational leadership and direction for Clarus’s commercialization
                                            of JATENZO in close concert with inVentiv Commercial Services (a Syneos HealthTM group
                                            company) that Clarus has selected as its commercial outsourcing partner (COP);

		●	Identify,
                                            hire and build a small (yet highly competent) internal sales and marketing management team
                                            to ensure commercial success of JATENZO (Note: you will work with the COP, Clarus’s
                                            CEO and CFO to determine minimal internal Clarus staff);

		●	Develop
                                            and implement, with COP, an integrated marketing and sales strategic plan for JATENZO;

		●	Regularly
                                            analyze JATENZO sales performance against plan and take all necessary actions to ensure sales
                                            goals are achieved;

		●	Provide
                                            exceptional leadership of all levels of the commercial team;

		●	Working
                                            with COP, ensure appropriate coverage of JATENZO by commercial and governmental payors to
                                            achieve forecasted success;

		●	Ensure
                                            operational capabilities/metrics to accurately track JATENZO sales and prepare accurate sales
                                            forecasts;

		●	Effectively
                                            leverage market dynamics and knowledge to position JATENZO as the top T-replacement products
                                            in the U. S. with the goal of having JATENZO be the market-leader within 5 years of launch;

		●	Set
                                            a high ethical standard for the marketing and sales organization;

		●	Function
                                            as a key executive of Clarus and work with other senior level personnel to ensure the overall
                                            success of the company;

		●	Participate
                                            with other Clarus executives in efforts designed to raise capital and/or embark on a strategic
                                            process to sell Clarus or, alternatively, take Clarus public; and

		●	Such
                                            other duties as Clarus may assign from time to time.

 

    1 

     

    

 

Your
starting salary will be at the rate of $325,000 per year paid in semi-monthly installments. Future salary increases will be at the discretion
of Clarus’s Board of Directors (the “Board”). In further consideration of your position at Clarus and subject to final
Board approval, Clarus will grant you an option to purchase 350,000 shares of common stock at its fair market value as of the grant date
(the “Initial Grant”). The options will vest in equal monthly installments over a 4-year period with a one-year cliff-vesting
provision. This means that no shares vest during the first 12 months of your employment whereupon 87,500 shares vest on the date of your
first anniversary. After this date, the remaining 262,500 shares will vest ratably over 36 months. However, if within one year of your
employment there is: (a) a merger or consolidation under which Clarus is not the surviving entity; (b) a sale of all or substantially
all of Clarus’ assets; (c) a reorganization or liquidation of Clarus; (d) you are terminated without “Cause” (as defined
herein); or (e) you resign for “Good Reason” (as defined herein), then one-half of the Initial Grant will immediately vest.
After one year of employment, should (a), (b), (c), (d), or (e) occur, your Initial Grant will vest immediately. The Initial Grant is
subject only to the terms and conditions of Clarus’ stock option plan and the associated stock option agreement (the “Equity
Documents”). Future grant awards may be made based on Company and individual employee performance. Clarus intends to use option
grants as a strong performance incentive.

 

In
addition to your base salary and stock options, you will be eligible for an annual bonus based on the achievement of corporate and individual
objectives as approved by the Board. Your bonus target will be 30% of your base salary and will take into account what fraction of the
year you were employed by Clarus. The decision to award bonuses rests solely with the Board and there is no guarantee that a bonus will
be awarded to you. You must be employed with Clarus on the date the bonus is paid to earn any part of the bonus.

 

Clarus
also will pay you a signing bonus of $100,000 within 30 days of the Start Date. If during the six month period following the Start Date
either, (i) you were to resign your position without Good Reason, (ii) a court of competent jurisdiction enters an injunction prohibiting
you from working for Clarus; or (iii) you are terminated by the Company with Cause, you must repay the signing bonus amount to Clarus
within ten (10) days of the date when your employment with Clarus ceases.

 

Clarus
currently provides medical/dental/vision benefits as outlined on the attached benefits summary. Should you choose not to avail yourself
of these benefits, you will not be compensated for this decision.

 

In
addition to Company holidays, as noted in the attachment hereto, you will also earn on a pro-rata basis twenty five (25) days of paid
vacation per calendar year. For 2019, your vacation days will be prorated on the basis of your Start Date. If you are unable to use all
of your vacation in any one year because the workload at Clarus is such that it is not possible for you to do so, you may rollover up
to 5 days to the next year but may not have a cumulative total of vacation days in excess of thirty (30) days.

 

Your
employment shall be at will, meaning you or the Company can terminate it at any time. In the event your employment ends for any reason,
Clarus shall pay your salary plus accrued but unused vacation though the termination date. In addition, in the event Clarus terminates
your employment without Cause (as defined below), or you resign for Good Reason (as defined below), and provided you enter into, do not
revoke, and comply with the terms of a separation agreement in a form acceptable to Clarus which shall include a general release against
Clarus and related persons and entities (the “Release”); Clarus will continue your base salary for the six (6) month period
that immediately follows the date of termination (the “Salary Continuation Payments”). Salary Continuation Payments shall
commence within 30 days after the Date of Termination and shall be made on Clarus’s regular payroll dates; provided, however, that
if the 30-day period begins in one calendar year and ends in a second calendar year, the Salary Continuation Payments shall begin to
be paid in the second calendar year. In the event you miss a regular payroll period between the date of termination and first Salary
Continuation Payment date, the first Salary Continuation Payment shall include a “catch up” payment. For purposes of this
letter agreement, “Cause” means: (i) conduct by you in connection with your service to Clarus that is fraudulent, unlawful
or grossly negligent; (ii) your material breach of your material responsibilities to Clarus or your willful failure to comply with reasonable
and lawful directives of the CEO or written policies of Clarus, which has not been cured within thirty (30) days’ written notice
by Clarus; (iii) breach by you of your representations, warranties, covenants and/or obligations under this Agreement, which has not
been cured within thirty (30) days’ written notice by Clarus; (iv) material misconduct by you which seriously discredits or damages
Clarus, which has not been cured within thirty (30) days’ written notice by Clarus ;and/or (v) nonperformance or unsatisfactory
performance of your material duties or responsibilities to Clarus as determined in good faith by Clarus, which has not been cured within
thirty (30) days’ written notice by Clarus . For purposes of this letter agreement, “Good Reason” means: (i) breach
by Clarus of its representations, warranties, covenants and/or obligations under this Agreement, which has not been cured within thirty
(30) days’ written notice by you; (ii) a reduction in your salary without your written consent; and/or (iii) a material reduction
in your job title and/or primary and then-current responsibilities, which has not been cured within thirty (30) days’ written notice
by you.

 

    2 

     

    

 

Frank,
I believe that your contributions to Clarus will be significant and immediate. You will be joining a team that is committed to successfully
commercializing JATENZO and making it the market-leading testosterone replacement therapy. Of greater importance from my perspective
is the opportunity we will have to positively impact the health of hypogonadal men who are prescribed JATENZO.

 

Finally,
as a condition of your employment, you must sign the attached Inventions, Confidentiality and Noncompetition Agreement (the “Restrictive
Covenant Agreement”), the terms of which are incorporated by reference into this letter agreement. Also, by your acceptance of
this employment offer, you attest that there are no current bars (e.g., non-compete provision with your current employer) to reasonably
prevent or interfere with your employment at Clarus, provided the Company acknowledges that it is aware of your prior employment contract
with AbbVie/Abbott and that neither you nor the Company views your employment with Clarus to be violative of the noncompete provisions.
In the event that you are made a party or threatened to be made a party to any action, suit, or proceeding, whether civil, criminal,
administrative or investigative, by reason of the fact that you are or were a director, manager, officer, or employee of Clarus, or any
affiliate of Clarus, including any action, suit, or proceeding, you shall be indemnified and held harmless by Clarus to the maximum extent
permitted under applicable law. Clarus shall pay all costs and reasonable expenses (including attorneys’ fees) incurred in defense
of any such action, suit, or proceeding.

 

This
agreement shall inure to the benefit of and be binding upon you and Clarus, and each of our respective successors, executors, administrators,
heirs and permitted assigns.

 

This
agreement, including the Restrictive Covenant Agreement and the Equity Documents, constitute the complete agreement between you and Clarus,
contain all of the terms of your employment with Clarus and supersede any prior agreements, representations or understandings (whether
written, oral or implied) between you and Clarus. The terms of this Agreement and the resolution of any disputes as to the meaning, effect,
performance or validity of this Agreement or arising out of, related to, or in any way connected with, this Agreement, your employment
with Clarus or any other relationship between you and Clarus (the “Disputes”) will be governed by Illinois law, excluding
laws relating to conflicts or choice of law. You and Clarus submit to the exclusive personal jurisdiction of the federal and state courts
located in the State of Illinois in connection with any Dispute or any claim related to any Dispute.

 

This
Agreement may not be modified or amended, and no breach shall be deemed to be waived, unless agreed to in writing by you and a duly authorized
officer or Board member of Clarus. This Agreement may be executed in two or more counterparts, each of which shall be an original and
all of which together shall constitute one and the same instrument.

 

Please
indicate your acceptance of this offer by signing below and returning a copy of this letter to me by mail, email or by facsimile no later
than September 6, 2019.

 

Best regards,

 

	/s/ Robert E. Dudley	 
	Robert E. Dudley, PhD	 
	President & CEO	 

 

	ACCEPTANCE:	/s/ Frank A. Jaeger	 	September 5, 2019	 
	 	Frank A. Jaeger	 	Date	 

 

 

 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]